Cargando…

Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial

INTRODUCTION: Immunoglobulin G4-related disease (IgG4-RD) is a debilitating multiorgan disease characterized by recurring flares leading to organ dysfunction, decreased quality of life, and mortality. Glucocorticoids, the standard of care for IgG4-RD, are associated with substantial treatment-relate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perugino, Cory, Culver, Emma L., Khosroshahi, Arezou, Zhang, Wen, Della-Torre, Emanuel, Okazaki, Kazuichi, Tanaka, Yoshiya, Löhr, Matthias, Schleinitz, Nicolas, Falloon, Judith, She, Dewei, Cimbora, Daniel, Stone, John H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654302/ https://www.ncbi.nlm.nih.gov/pubmed/37792260 http://dx.doi.org/10.1007/s40744-023-00593-7

Ejemplares similares

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial
por: Rensel, Mary, et al.
Publicado: (2021)

Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders
por: Yan, Li, et al.
Publicado: (2022)

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD
por: Cree, Bruce AC, et al.
Publicado: (2021)

Development of an IgG4-RD Responder Index
por: Carruthers, Mollie N., et al.
Publicado: (2012)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
por: Marignier, Romain, et al.
Publicado: (2021)

Inebilizumab: First Approval
por: Frampton, James E.
Publicado: (2020)

Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis
por: Wallwork, Rachel, et al.
Publicado: (2018)

Large vessel involvement by IgG4-related disease
por: Perugino, Cory A., et al.
Publicado: (2016)

Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis
por: Yan, Li, et al.
Publicado: (2021)

IgG4-Related Disease
por: Stone, John H., et al.
Publicado: (2013)

IgG4-Related Disease and Hypertrophic Pachymeningitis
por: Wallace, Zachary S., et al.
Publicado: (2013)

Are Classification Criteria for IgG4-RD Now Possible? The Concept of IgG4-Related Disease and Proposal of Comprehensive Diagnostic Criteria in Japan
por: Okazaki, Kazuichi, et al.
Publicado: (2012)

Current perspectives on autoimmune pancreatitis and IgG4-related disease
por: OKAZAKI, Kazuichi, et al.
Publicado: (2018)

IgG4-Related Disease Is Not Associated with Antibody to the Phospholipase A2 Receptor
por: Khosroshahi, Arezou, et al.
Publicado: (2012)

Current status of type 1 (IgG4-related) autoimmune pancreatitis
por: Uchida, Kazushige, et al.
Publicado: (2022)

Rethinking Ormond’s Disease: “Idiopathic” Retroperitoneal Fibrosis in the Era of IgG4-Related Disease
por: Khosroshahi, Arezou, et al.
Publicado: (2013)

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
por: Aktas, Orhan, et al.
Publicado: (2023)

Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Nie, Tina, et al.
Publicado: (2022)

Prevalence of IgG4-Related Disease in Japan Based on Nationwide Survey in 2009
por: Uchida, Kazushige, et al.
Publicado: (2012)

Current concept and diagnosis of IgG4-related disease in the hepato-bilio-pancreatic system
por: Okazaki, Kazuichi, et al.
Publicado: (2013)

Sclerosing Esophagitis with IgG4-positive Plasma Cell Infiltration
por: Mori, Shigeo, et al.
Publicado: (2017)

Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Nie, Tina, et al.
Publicado: (2022)

IgG4-related disease: Changing epidemiology and new thoughts on a multisystem disease
por: Floreani, Annarosa, et al.
Publicado: (2020)

Recent Advances in the Concept and Pathogenesis of IgG4-Related Disease in the Hepato-Bilio-Pancreatic System
por: Okazaki, Kazuichi, et al.
Publicado: (2014)

A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details
por: Umehara, Hisanori, et al.
Publicado: (2011)

Implication of allergy and atopy in IgG4-related disease
por: D’Astous-Gauthier, Katherine, et al.
Publicado: (2023)

Phospholipase A2 receptor–associated membranous nephropathy in a patient with IgG4-related disease: A case report
por: Muhsin, Saif A., et al.
Publicado: (2019)

Serum IgG4 level predicts COVID-19 related mortality
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

Pathologies Associated with Serum IgG4 Elevation
por: Ebbo, Mikael, et al.
Publicado: (2012)

Thoracic manifestations of IgG4‐related disease
por: Muller, Romain, et al.
Publicado: (2022)

Serum IgG4 elevation in hyper-inflamed COVID-19 patients. Author's reply
por: Della-Torre, Emanuel, et al.
Publicado: (2022)

Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis
por: Plichta, Damian R., et al.
Publicado: (2021)

Antineutrophil cytoplasmic antibody positivity in IgG4-related disease: A case report and review of the literature
por: Della-Torre, Emanuel, et al.
Publicado: (2016)

Pulmonary IgG4‐related disease with favourable response to rituximab: A case report
por: Muller, Romain, et al.
Publicado: (2022)

IgG4‐related disease: Association with a rare gene variant expressed in cytotoxic T cells
por: Newman, John H., et al.
Publicado: (2019)

IgG4-type Multiple Myeloma with Diffuse Enlargement of the Thyroid Requiring Differentiation from IgG4-related Disease
por: Funada, Masashi, et al.
Publicado: (2020)

Review of primary sclerosing cholangitis with increased IgG4 levels
por: Manganis, Charis D, et al.
Publicado: (2020)

Serum IgG4-negative IgG4-related disease with a cardiac mass: A case report
por: Namba, Kensuke, et al.
Publicado: (2023)

Subclasses of allergen-specific IgG: Serum IgG2 and IgG3 levels are not predicted by IgG1/IgG4 levels
por: MacGlashan, Donald, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i2gg1j0kdu1npra7jf3jhte1gb